Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles
- PMID: 16303268
- DOI: 10.1016/j.ijpharm.2005.10.010
Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles
Abstract
The process of opsonization is one of the most important biological barriers to controlled drug delivery. Injectable polymeric nanoparticle carriers have the ability to revolutionize disease treatment via spatially and temporally controlled drug delivery. However, opsonin proteins present in the blood serum quickly bind to conventional non-stealth nanoparticles, allowing macrophages of the mononuclear phagocytic system (MPS) to easily recognize and remove these drug delivery devices before they can perform their designed therapeutic function. To address these limitations, several methods have been developed to mask or camouflage nanoparticles from the MPS. Of these methods, the most preferred is the adsorption or grafting of poly(ethylene glycol) (PEG) to the surface of nanoparticles. Addition of PEG and PEG-containing copolymers to the surface of nanoparticles results in an increase in the blood circulation half-life of the particles by several orders of magnitude. This method creates a hydrophilic protective layer around the nanoparticles that is able to repel the absorption of opsonin proteins via steric repulsion forces, thereby blocking and delaying the first step in the opsonization process.
Similar articles
-
In vivo tumor targeting of tumor necrosis factor-alpha-loaded stealth nanoparticles: effect of MePEG molecular weight and particle size.Eur J Pharm Sci. 2006 Jan;27(1):27-36. doi: 10.1016/j.ejps.2005.08.002. Epub 2005 Sep 16. Eur J Pharm Sci. 2006. PMID: 16150582
-
Body distribution and in situ evading of phagocytic uptake by macrophages of long-circulating poly (ethylene glycol) cyanoacrylate-co-n-hexadecyl cyanoacrylate nanoparticles.Acta Pharmacol Sin. 2005 Dec;26(12):1512-8. doi: 10.1111/j.1745-7254.2005.00216.x. Acta Pharmacol Sin. 2005. PMID: 16297352
-
Shielding Therapeutic Drug Carriers from the Mononuclear Phagocyte System: A Review.Crit Rev Ther Drug Carrier Syst. 2016;33(6):489-567. doi: 10.1615/CritRevTherDrugCarrierSyst.2016012303. Crit Rev Ther Drug Carrier Syst. 2016. PMID: 27992308 Review.
-
Influence of PEG chain on the complement activation suppression and longevity in vivo prolongation of the PCL biomedical nanoparticles.Biomed Microdevices. 2009 Dec;11(6):1187-94. doi: 10.1007/s10544-009-9336-2. Biomed Microdevices. 2009. PMID: 19609680
-
Assessment of PEG on polymeric particles surface, a key step in drug carrier translation.J Control Release. 2014 Jul 10;185:71-87. doi: 10.1016/j.jconrel.2014.04.017. Epub 2014 Apr 22. J Control Release. 2014. PMID: 24768790 Review.
Cited by
-
Nano-gold corking and enzymatic uncorking of carbon nanotube cups.J Am Chem Soc. 2015 Jan 21;137(2):675-84. doi: 10.1021/ja511843w. Epub 2015 Jan 7. J Am Chem Soc. 2015. PMID: 25530234 Free PMC article.
-
PLGA Nanoparticle-Based Formulations to Cross the Blood-Brain Barrier for Drug Delivery: From R&D to cGMP.Pharmaceutics. 2021 Apr 6;13(4):500. doi: 10.3390/pharmaceutics13040500. Pharmaceutics. 2021. PMID: 33917577 Free PMC article. Review.
-
Cell Membrane-Based Biomimetic Nanoparticles and the Immune System: Immunomodulatory Interactions to Therapeutic Applications.Front Bioeng Biotechnol. 2020 Jun 17;8:627. doi: 10.3389/fbioe.2020.00627. eCollection 2020. Front Bioeng Biotechnol. 2020. PMID: 32626700 Free PMC article. Review.
-
Stealth properties to improve therapeutic efficacy of drug nanocarriers.J Drug Deliv. 2013;2013:374252. doi: 10.1155/2013/374252. Epub 2013 Mar 7. J Drug Deliv. 2013. PMID: 23533769 Free PMC article.
-
Ultrasmall superparamagnetic iron oxide nanoparticles acutely promote thrombosis and cardiac oxidative stress and DNA damage in mice.Part Fibre Toxicol. 2016 Apr 30;13(1):22. doi: 10.1186/s12989-016-0132-x. Part Fibre Toxicol. 2016. PMID: 27138375 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources